Publications by authors named "A F Hajj-Ali"
Clinical features and temporal trends in H. pylori negative gastric maltoma.
Arab J Gastroenterol
January 2025
Article Synopsis
- Mucosa-Associated Lymphoid Tissue (MALT) lymphoma, particularly gastric MALToma, is often associated with Helicobacter pylori (H. pylori) infection, though a significant number of cases occur without it.
- A study analyzed 52 patients with gastric MALToma from 2000 to 2021, finding that 48.1% were H. pylori-negative (HPN) and noted trends of increased HPN diagnoses in more recent years.
- Treatment outcomes showed that HPP patients had better responses to eradication therapy compared to HPN patients, who were more likely to receive additional chemo or radiotherapy.
- Despite these differences in treatment response, clinical features between HPP and HPN patients
Background: Apical hypertrophic cardiomyopathy (aHCM) is a distinct variant characterized by predominant hypertrophy of the left ventricle apex.
Objectives: This study sought to describe aHCM patients' characteristics and develop a risk score for aHCM patients.
Methods: A total of 462 patients (age 58 ± 15 years, 68% male) diagnosed with aHCM were included.
Introduction: Following ileocolic resection (ICR), the clinical importance and prognostic implications of histologic activity on biopsies in Crohn's disease (CD) patients with endoscopic remission are not well defined. The aim of this study was to determine if histologic activity in patients with endoscopic remission is associated with future risk of endoscopic and/or radiologic postoperative recurrence (POR).
Methods: In this multicenter retrospective cohort study, adult patients with CD who underwent ICR between 2009 and 2020 with endoscopic biopsies of ileal mucosa from Rutgeerts i0 on index colonoscopy were included.
Article Synopsis
- Mavacamten is approved for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and aims to improve left ventricular outflow tract gradients and reduce the need for septal reduction therapy (SRT).
- A study of 150 patients showed significant improvements in New York Heart Association (NYHA) class and reduced LVOT gradients after 12 weeks of mavacamten treatment, with 46% of patients showing at least one class improvement.
- Although there was a slight decline in left ventricular ejection fraction (LVEF), no patients required SRT or experienced severe heart failure complications during the study period.